Development of a new eye-tracking software for Alzheimer's Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on creating and validating a non-invasive eye-tracking software application designed to assess cognitive functions affected by Alzheimer's Disease. Participants will undergo brief cognitive tests alongside eye movement measurements in response to visual stimuli during specialized eye-tracking assessments. The collected data will be utilized to develop machine learning algorithms aimed at tracking the progression of Alzheimer's Disease and its associated cognitive changes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* For all participants:

  1. Able to provide informed consent
  2. Aged 18 years or older at the time of enrollment
  3. Able to read in either French or English
  4. Able to read the oculomotor task on-screen instructions at the testing distance (45cm) with or without corrective lenses.
* For patients only:

  1. Confirmed diagnosis of AD based on the NIAAA diagnostic criteria of probable AD

Exclusion Criteria:

* For AD participants:

  1. Diagnosed with one of the following dementia subtypes: Fronto-temporal dementia, Lewy-body dementia, or Creutzfeldt-Jakob disease.
  2. Incapacity to provide informed consent or inability to adequately understand the task instructions.
* For all participants:

  1. Evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control.
  2. Presence of comorbid neurological conditions to avoid eye movement anomaly confounds (strabismus, cranial nerve palsy, stroke-causing hemianopsia).
  3. Diagnosis of macular edema or other pre-existing ocular conditions (e.g., glaucoma, cataracts) that would prevent from performing the eye movement assessments.
  4. Unstable medication use: recent (less than one month from enrollment) start of, change of dose, or irregular use of, new prescription drugs known to have an effect on ocular motor visual function, such as benzodiazepines, antipsychotics and anticonvulsants. Occasional use of benzodiazepines for medical procedures is permitted, at the investigator's discretion, but should not occur within a short time period of an eye movement assessment.
  5. Diagnosed with an active substance use disorder.
  6. History of stroke may be considered an exclusion criterion, at the discretion of the PI, if judged to potentially affect the cerebral network underlying eye movements and gaze control.
  7. Recent traumatic brain injury (within the last 6 months).
* For healthy controls only:

  1. Evidence or history of significant neurodegenerative disorder affecting brain function (e.g., MS, PD, ALS, Non-AD Dementia).

Where it's running

• Elogia, a Residence of Groupe Maurice
  Montreal, Quebec, Canada Recruiting
• Cornelius, a Residence of Groupe Maurice
  Montreal, Quebec, Canada Recruiting
• The Douglas Research Centre
  Montreal, Quebec, Canada Recruiting
• The Montreal Neurological Institute
  Ville-Marie, Quebec, Canada Recruiting
• ORA, A residence of Groupe Maurice
  Montreal, Quebec, Canada Not yet recruiting

Study contacts

• Study coordinator: Luciano Buonamici
• Email: luciano.buonamici@mcgill.ca
• Phone: 514-399-9016

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acoustic Stimulation During Sleep for Alzheimer’s Disease

  Researchers test whether playing gentle sounds during sleep can help people with Alzheimer’s disease see if their thinking improves compared with a sham sound.

  Recruiting Xuanwu Hospital, Beijing · Beijing · NCT07924657

• FAME: A Italian test to recognize famous faces and name them

  This project tests an Italian battery to see how well people with stroke or neurodegenerative diseases recognize famous faces and recall their names, familiarity, and related facts.

  Recruiting at 8 sites Istituti Clinici Scientifici Maugeri SpA · Sciacca, AG and 9 other locations · NCT07911878

• NMS-01 safety test in people with mild to moderate Alzheimer's disease

  This pilot test checks whether the focused ultrasound device NMS-01 is safe and can briefly open the blood-brain barrier in adults with mild-to-moderate Alzheimer's disease.

  Recruiting Neumous Inc. · Seoul, Seodaemun · NCT07869238

• Choose Myself (Before) Losing Myself

  We’re testing an educational interactive booklet to help people with dementia or memory problems think about future medical decisions and start conversations with family or caregivers.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT07846566

• Lecanemab-irmb in Real-World Use for Alzheimer’s Disease

  This study tests the safety of lecanemab-irmb in people with Alzheimer’s disease by looking at real-world brain-image changes and related events.

  Recruiting Eisai Inc. · Nutley, New Jersey · NCT07821658

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.